Merrill Lynch Upgrades Amylin Pharmaceuticals (AMLN) to Buy
More News related to AMLN
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
- Amylin Pharmaceuticals (AMLN): Upgraded to Overweight at Barclays, target raised to $22
- Barclays Upgrades Amylin Pharmaceuticals (AMLN) to Overweight
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
More News related to Upgrades
- Satyam (SAY) Jumps 5% as JPMorgan Issues Intraday Upgrade
- Credit Suisse Upgrades MDC Holdings (MDC) to Neutral, $29 Target
- BMO Capital Upgrades EMCOR Group (EME) to Outperform
- BMO Capital Upgrades Catalyst Health Solutions (CHSI) to Outperform
- Morgan Stanley Upgrades P.F. Chang's China Bistro (PFCB) to Overweight
Merrill Lynch upgrades Amylin Pharmaceuticals (Nasdaq: AMLN) from Neutral to Buy.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.
Related Categories
UpgradesStocks Mentioned
+0.26Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
